Treatment of IgA nephropathy  by Barratt, J. & Feehally, J.
Treatment of IgA nephropathy
J Barratt1 and J Feehally1
1The John Walls Renal Unit, Department of Infection, Immunity and Inflammation, Leicester General Hospital, University of Leicester,
Leicester, UK
IgA nephropathy (IgAN) is an important cause of progressive
kidney disease with 25–30% of patients developing end-stage
renal disease within 20 years of diagnosis. There is still no
treatment to modify mesangial IgA deposition and available
treatments are those extrapolated from the management of
other patterns of chronic glomerulonephritis. There remains
no consensus on the use of immunosuppressive agents for
treatment of progressive IgAN and this is compounded by
the relative lack in IgAN of randomized controlled trials
relevant to current clinical practice. Patients with recurrent
macroscopic hematuria or isolated microscopic hematuria
and proteinuria o1 g/24 h require no specific treatment.
Those with nephrotic syndrome and minimal change on
renal biopsy should be managed as for minimal change
nephropathy. There is no evidence to support the use of
corticosteroids for nephrotic IgAN outside this group of
patients. Patients presenting with acute renal failure require
evaluation to distinguish acute tubular necrosis, which
requires supportive therapy only, from crescentic IgAN, for
which treatment with cyclophosphamide and corticosteroids
in a regimen similar to that for renal small vessel vasculitis is
indicated in the absence of significant chronic histologic
injury. Patients at greatest risk of progressive renal
impairment are those with hypertension, proteinuria 41 g/
24 h, and reduced glomerular filtration rate at diagnosis. All
such patients should be treated to a blood pressure of 125/
75 mm Hg with dual blockade of the renin–angiotensin
system with angiotensin-converting enzyme inhibition and
angiotensin receptor blockade. At present, there is
insufficient evidence for the additional use of
immunosuppressive agents, antiplatelet agents, or
anticoagulants.
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Immunoglobulin A nephropathy (IgAN) is the most
common pattern of idiopathic glomerulonephritis in all
countries where renal biopsy is widely practiced. It is an
important cause of end-stage renal disease (ESRD) at all ages,
and therefore treatment strategies to reduce the risk of IgAN
progressing to ESRD would have substantial health benefit.
There are, however, few well-designed randomized controlled
trials (RCTs) to inform the treatment of this condition. The
reason for this is in part the slow rate of progression of IgAN,
making it necessary to study large numbers of patients for
prolonged periods of time to determine the efficacy of
any therapeutic intervention. Another consequence of the
slowly progressive nature of IgAN is that for many of the
trials now published patient recruitment occurred at a time
when the management of progressive glomerular disease was
less clearly defined than it is now.
In this review, we will critically evaluate the available
evidence on the treatment of IgAN, especially focusing
on recently published RCTs; earlier available data have been
reviewed elsewhere.1 We will also provide recommendations
for the common clinical situations that confront the
nephrologist treating patients with IgAN.
CLINICAL PRESENTATIONS AND DIAGNOSIS
Asymptomatic urine abnormalities, microscopic hematuria
with or without proteinuria, are a common presentation
and with increasing age these features are more likely to be
accompanied by renal impairment and hypertension when
first seen. The typical presentation of macroscopic hematuria
following a mucosal (usually upper respiratory) infection
is most common in the second and third decades of life
and is almost never the presenting symptom after the age of
40 years. Nephrotic syndrome occurs in around 5% of cases.
Acute renal failure may result from acute tubular necrosis as
a consequence of macroscopic hematuria or superimposed
crescentic nephritis and is seen during the course of the
disease in o5% of cases.
Renal biopsy confirms the diagnostic feature of diffuse
mesangial IgA deposition with a wide range of light
microscopic appearances, although diffuse or segmental
mesangial proliferation is the most common.
NATURAL HISTORY AND PROGNOSIS
Resolution of urinary abnormalities occurs in less than 10%
of all patients. More commonly, IgAN is associated with
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slowly progressive chronic renal impairment with between 25
and 30% of any cohort developing ESRD within 20–25 years
of presentation. Local variations in the perceived risk of
ESRD in IgAN stem primarily from the different diagnostic
approaches adopted internationally. Centers with a low
threshold for renal biopsy for patients with mild urine
abnormality, particularly in countries with active urine
screening programs, are more likely to diagnose mild disease
with good prognosis, thus favorably influencing the overall
outcome of the cohort.
Adverse clinical features at presentation include protein-
uria, hypertension, and reduced glomerular filtration rate
(GFR), and adverse histopathologic features include glome-
rular sclerosis, tubular atrophy, and interstitial fibrosis.2
None of the features that mark a poor prognosis are specific
to IgAN, and would be applicable to any form of chronic
proteinuric glomerular disease. They are informative for
populations of patients, but as yet do not have the specificity
to identify an individual prognosis with complete confidence.
An approach incorporating sequential information on
blood pressure (BP) and proteinuria can further refine the
prediction of progression risk, although this will still only
account for 30% of overall risk. Although prognostic
formulae using simple clinical and laboratory data have been
proposed, there is not yet sufficient consensus to recommend
their use in clinical practice for the prediction of individual
progression risk. It also remains uncertain whether patho-
logical classification adds to predictive power in the indi-
vidual patient; progress in defining the answer has been
limited by the lack of an international consensus on patho-
logical classification of IgAN. Further refinement of prog-
nostic prediction will inform recruitment criteria for future
interventional treatment trials.
Recurrence of IgAN after renal transplantation is assuming
increasing importance as a cause of graft failure as control of
rejection improves. The diagnosis and management of
recurrence have recently been reviewed in detail,3 and we
will not here consider this further.
TREATMENT STRATEGIES
There is still no treatment known to modify mesangial
deposition of IgA. Available treatment options are mostly
directed at downstream immune and inflammatory events
in the glomerulus and the tubulo-interstitium, which may
lead on to renal scarring. It is therefore likely that these are
generic treatments with potential benefit in other chronic
glomerular diseases.
Here we will review the available treatments from
the perspective of each clinical presentation encountered
in IgAN; treatment recommendations are summarized in
Table 1.
Recurrent macroscopic hematuria
Such episodes are self-limiting, and provoked by a range of
mucosal, most commonly respiratory, infections. There is
no role for prophylactic antibiotics, even in the minority
of patients in whom recurrent episodes are provoked by
bacterial tonsillitis. Tonsillectomy is still favored in some
regions of the world, notably Japan. Tonsillectomy may help
to prevent episodic macroscopic hematuria in the short term,
and proponents of tonsillectomy argue that it also gives
long-term renal protection. This view is supported by two
large retrospective studies from Japan, although benefit was
not apparent until 10 years after tonsillectomy.4,5 The
concomitant use of other treatment modalities and changing
therapeutic goals during the follow-up period make these
data difficult to interpret; a retrospective study from
Germany suggests no benefit of tonsillectomy.6 An RCT of
tonsillectomy in IgAN is now being planned in Japan.
In our opinion, no specific treatment is required for
patients with IgAN presenting with recurrent macroscopic
hematuria and preserved GFR.
Table 1 | Treatment recommendations for IgAN according to clinical features
Clinical presentation Recommended treatment
Recurrent macroscopic hematuria with preserved renal function No specific treatment – no role for antibiotics or tonsillectomy
Proteinuria o1 g/24 h7microscopic hematuria No specific treatment
Proteinuria 41 g/24 h7microscopic hematuria Combined renin–angiotensin blockade with ACE inhibitor and ARB
Acute renal failure
Acute tubular necrosis Supportive measures
Crescentic IgAN (with little or no chronic damage)
Induction (B8 weeks) Prednisolone 0.5–1 mg/kg/day
Cyclophosphamide 2 mg/kg/day
Maintenance Prednisolone in reducing dosage
Azathioprine 2.5 mg/kg/day
Nephrotic syndrome
With minimal change on light microscopy Prednisolone 0.5–1 mg/kg/day for up to 8 weeks
With structural glomerular changes No specific treatment
Hypertension Target BP 125/75 mm Hg if proteinuria 41 g/24 h
ACE inhibitors/ARB first choice agents
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; IgAN, IgA nephropathy.
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Isolated microscopic hematuria and little or no proteinuria
It is generally accepted that no specific treatment is required,
although patients should receive regular follow-up. A
threshold for proteinuria of 1 g/24 h is commonly used to
identify those at increased risk of progression, although this
is an arbitrary value, and the risk attributable to proteinuria
is almost certainly a continuum.
Acute renal failure
Acute renal failure is an uncommon event in IgAN and most
commonly occurs with macroscopic hematuria. Even if the
diagnosis of IgAN has previously been established, evaluation
should include renal biopsy unless renal function improves
within 2–3 days of supportive treatment. The biopsy will
distinguish between ARF owing to acute tubular necrosis,
which should be self-limiting with continuing supportive
treatment, and crescentic IgAN, which may be amenable to
intensive immunosuppression (see below).
Crescentic IgAN
Crescentic IgAN has a less good prognosis despite immuno-
suppressive therapy than other forms of crescentic glomerulo-
neprhitis, for example, that associated with antineutrophil
cytoplasmic antibody-positive small vessel vasculitis; cumula-
tive published cases suggest that renal survival in crescentic
IgAN is only 50% at 1 year and 20% at 5 years. A number of
optimistic case series have recently been published indicating
good preservation of renal function using treatment regimens
similar to those recommended for renal vasculitis, usually
with high-dose corticosteroids and cyclophosphamide, and
in some cases, plasma exchange (reviewed by Tumlin and
Hennigar7). However there has still been no RCT of these
treatments in crescentic IgAN, and response to treatment is
not uniform. There is a lack of clarity because published
reports use varying definitions of crescentic IgAN, for
example, some include cases where crescents are seen, but
other acute injury to the glomerular tuft is not intense and
renal function is not deteriorating. One report indicates that
there is a subset of crescentic IgAN with circulating
antineutrophil cytoplasmic antibodies, which respond well
to immunosuppression.8 Crescentic IgAN may occur as the
first presentation of IgAN with little preceding renal insult;
on the other hand, it is not uncommon to see crescentic
change on a background of chronic glomerular and tubulo-
interstitial injury; such chronicity usually predicts a poor
response to intensive immunosuppression.
We only recommend immunosuppressive treatment with
cyclophosphamide and corticosteroids when crescentic IgAN
(410% of glomeruli affected by crescents) is associated with
active glomerular inflammation and deteriorating renal
function in the absence of significant chronic damage
(Table 1).
Nephrotic syndrome in IgAN
In many patients with IgAN and nephrotic syndrome, the
heavy proteinuria is a manifestation of significant structural
glomerular damage and progressive renal dysfunction.
However, a small minority, both adults and children, have
nephrosis with minimal glomerular change on renal biopsy,
although there are also IgA deposits, and proteinuria remits
promptly in response to corticosteroids. In these patients,
two common glomerular diseases may coincide: minimal-
change nephrotic syndrome and IgAN.9,10 This observation
justifies a trial of high-dose corticosteroids using a regimen
appropriate for minimal-change disease in IgAN with
nephrotic syndrome and preserved renal function when light
microscopy shows minimal glomerular injury. However,
there is no evidence to support prolonged exposure to
corticosteroids if there is neither a prompt response nor their
use in nephrotic syndrome in the presence of structural
glomerular damage. The only RCT of corticosteroids in
nephrotic IgAN confirms this approach as there was
remission of proteinuria only in patients with minimal
glomerular change on light microscopy.11 More recent RCTs
of corticosteroids in IgAN have excluded those with
nephrotic-range proteinuria, so there is little evidence to
inform treatment choices for nephrotic IgAN with significant
histologic glomerular injury.
Other than patients with IgAN and histological features
of minimal change, we do not recommend the use of
corticosteroids for the treatment of nephrotic syndrome in
IgAN.
Slowly progressive IgAN
Patients at risk of progressive renal dysfunction are typically
those with hypertension, proteinuria 41 g/24 h, or reduced
GFR at the time of diagnosis. Specific treatment strategies in
this group of patients remain contentious. Progression is
usually slow and therefore large studies with prolonged
follow-up are necessary to evaluate new treatment strategies
in these patients. Unfortunately, many of the published
studies in progressive IgAN have been insufficiently powered
and consequently no definitive conclusions on treatment
options can be made. Also, all trials in IgAN use clinical entry
criteria – typically the presence of hypertension and
proteinuria 1–3 g/24 h, with variable reduction in GFR. This
is in contrast, for example, to studies in lupus nephritis where
histological criteria usually dominate recruitment, and
reflects the lack of international consensus on a histopatho-
logical classification of IgAN.
BP control. The recommended approach to proteinuric
patients with glomerular disease emphasizes rigorous BP
control to a target of 125/75 mm Hg with maximal
renin–angiotensin system blockade to minimize protein-
uria.12 There is some specific evidence in IgAN to justify
tight BP control: in one small RCT, achieved mean BP of 129/
70 mm Hg stabilized GFR over 3 years, whereas patients with
achieved BP of 136/76 mm Hg showed a mean decline in GFR
of 13 ml/min over 3 years.13 Another small RCT supports the
additional benefit of an angiotensin-converting enzyme
inhibitor on progressive renal disease in IgAN despite
equivalent BP control by achieving an additional reduction
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in proteinuria.14 Furthermore, the COOPERATE study
provides evidence for additive renoprotection when an
angiotensin receptor blocker is given in combination with
an angiotensin-converting enzyme inhibitor in non-diabetic
proteinuric renal disease; additional reduction in proteinuria
being achieved with no further lowering of BP; 131 of the
patients in this large study had IgAN.15
Treatments modulating immune and inflammatory injury.
Recently reported RCTs have tested interventions intended to
slow immune and inflammatory events implicated in
progressive IgAN including corticosteroids, cyclophospha-
mide, and mycophenolate mofetil. Because of the long
duration required to identify with confidence the benefit of
interventions, it is inevitable that recruitment into a number
of these studies goes back 10 years or more, to a time
when the generic approach to progressive glomerular disease
was less well defined, so that BP targets and the use of
renin–angiotensin blockade are variable in these studies.
Corticosteroids: Six trials (341 patients) were considered
of sufficient quality to be included in a recent meta-analysis
of immunosuppressive treatments for IgAN.16 This analysis
suggests that corticosteroid therapy may be effective in
reducing proteinuria and reducing risk of ESRD. Follow-up
in the large Italian study of corticosteroids has now reached
10 years and reports impressive benefit from treatment in
reducing proteinuria and preventing ESRD.17.However, their
high-dose corticosteroid regimen, using ‘pulse’ methylpredni-
solone (1 g daily for 3 days at induction and beginning of
months 2 and 4) and alternate day oral prednisolone (0.5 mg/
kg) for 6 months, is regarded by many physicians as likely to
carry considerable toxicity, even though none is reported by
the investigators. Notably, renin–angiotensin system blockade
was only used in a minority of patients in this study, although
equally distributed among the participants, and achieved BP
was not in line with current recommendations (Table 2).
Another recent RCT of corticosteroids (20 mg/day induction;
5 mg/day maintenance) from Japan in which BP control was
tight even though renin–angiotensin system blockade was not
used (Table 2) showed only a modest reduction in
proteinuria with no protection of GFR.18 It is unclear
whether this lack of renoprotection was owing to the lower
dose of corticosteroid or a genuine lack of effect in patients
managed to current BP targets.
In our view, corticosteroids should be considered only
when there is continued proteinuria (41 g/24 h) despite
tight BP control (o125/75 mm Hg) and maximal renin–
angiotensin system blockade.
Cyclophosphamide: The use of cyclophosphamide in
patients at very high risk of progression (ESRD predicted
in all cases within 5 years) is supported by a single study.
Patients received cyclophosphamide (1.5 mg/kg/day for 3
months) followed by azathioprine (1.5 mg/kg/day) in con-
junction with high-dose prednisolone (40 mg/day induction;
10 mg/day maintenance) and were followed for at least 2
years.19 Notably, BP control and use of renin–angiotensin
system blockade in this trial fell outside current recommen-
dations (Table 2). Previous RCTs of cyclophosphamide in
less severe IgAN showed no consistent benefit (reviewed
by Feehally1).
In our opinion, there is insufficient evidence to support
the use of cyclophosphamide in IgAN, except in crescentic
IgAN with rapidly progressive renal failure (see above).
Mycophenolate mofetil: Two studies report no benefit from
mycophenolate mofetil (2 g/day) in patients either at risk of
progression (hypertensive and/or proteinuria 41 g/24 h and/or
reduced GFR within 5 years of diagnosis)20 or with more
advanced disease (mean serum creatinine at entry 2.6 mg/dl).21
Both of these studies achieved rigorous BP control with use of
an angiotensin-converting enzyme inhibitor (Table 2). In two
separate studies, mycophenolate mofetil (1–2 g/day) did reduce
proteinuria over an 18-month follow-up period; however,
neither study demonstrated a change in rate of renal
decline.22,23 Again both studies achieved tight BP control with
angiotensin-converting enzyme inhibition. The relatively small
size and short duration of the studies so far available justifies
further evaluation, and other studies are in progress.24
Table 2 | Treatment of IgAN and achieved BP and use of renin–angiotensin blockade in recently published RCTs
Treatment Benefit Achieved BP (mm Hg) ACE inhibitor or ARB
ACE inhibitor7ARB15 Reduction in proteinuria and preserved
GFR; best with ACE inhibitor plus ARB
125/70 ACE inhibitor or ARB or
combination
Corticosteroids17 Reduction in proteinuria and reduced
ESRD at 10 years
134/84 43% – used equally in both
study groups
Corticosteroids18 Small reduction in proteinuria; no effect on GFR 125/80 8% – most used in responders
Corticosteroids+
cyclophosphamide19
Renoprotection in
very high risk patients
145/85 Unclear
Mycophenolate mofetil20 None 125/73 100%
Mycophenolate mofetil21 None 129/81 100%
Mycophenolate mofetil22 Reduction in proteinuria; no effect on GFR Uncertain None
Mycophenolate mofetil23 Reduction in proteinuria; no effect on GFR 122/71 100%
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; ESRD, end-stage renal disease; GFR, glomerular filtration rate; IgAN, IgA
nephropathy; RCT, randomised controlled trial.
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In our opinion, there is insufficient evidence at present for
the use of mycophenolate mofetil for the treatment of
progressive IgAN.
Fish oil: The initial study of fish oil in IgAN reported
significant benefit in patients at risk of progression;25
however, there are still no further studies to support its role,
and a meta-analysis including other published studies does
not suggest efficacy.26 The preliminary report of a more
recent RCT shows no benefit following 2 years treatment with
fish oil compared to corticosteroids and placebo.27
On the available evidence, we do not recommend the use
of fish oil.
Coagulation modifying agents: Warfarin, urokinase, and anti-
platelet agents have all been assessed for the treatment of IgAN.
The earlier trials of these agents have been reviewed elsewhere.1
In our opinion, there is at the present time insufficient
evidence to support the use of warfarin, urokinase, or
antiplatelet agents.
Choice of therapy
This remains a controversial area, but in our opinion
adjunctive therapy with corticosteroids or other agents should
only be considered in patients with sustained proteinuria
41 g/24 h despite achieving target BP of 125/75 mm Hg with
full renin–angiotensin blockade. In our clinical experience,
there are few patients who fulfill these criteria, and it should be
recognized that the efficacy of corticosteroids, cyclopho-
sphamide, and mycophenolate mofetil has not been adequately
evaluated by RCT in the context of such a ‘standard regimen’.
It should also be noted in Table 2 that those studies in which
contemporary BP targets were achieved and full renin–angio-
tensin blockade deployed were those least likely to show
benefit from the additional therapy.
Furthermore, the recently published meta-analysis of
immunosuppressive treatments for IgAN, which suggested
benefit for corticosteroids and immunosuppressive agents,
was unable to include complete data on achieved BP or the
use of renin–angiotensin blockade and so the possibility that
these were confounding factors could not be evaluated.16
FUTURE PROGRESS
It is unfortunately becoming increasingly difficult to judge
the efficacy of any proposed new therapeutic intervention.
The renoprotective efficacy of the ‘standard regimen’ means
that evaluation of any additional intervention will require
increasingly large and prolonged RCTs to prove benefit for
additional agents unless robust surrogate measures of out-
come are developed to enable studies to be scaled down
without loss of power. Information from well-designed RCTs
remains a pressing priority if uncertainties in the treatment
of IgAN are to be resolved.
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